Alzheimer’s Disease Research, Ellison Foundation to Invest $6 Million in UW Medicine Precision Medicine Approach

Alzheimer’s Disease Research, Ellison Foundation to Invest $6 Million in UW Medicine Precision Medicine Approach
Currently incurable, Alzheimer's disease (AD) is projected by the Centers for Disease Control to afflict some 13.8 million people in the U.S. by 2050 if effective new treatments are not discovered. Already, millions of U.S. residents are living with severe, disabling, and progressively degenerative Alzheimer's-related dementia.   A new $6 million investment by the Ellison Foundation will enable the University of Washington Department of Medicine's Alzheimer's Disease Research Center (ADRC) to launch a unique new project that it says could revolutionize Alzheimer's patient care. The primary research focus of the ARDC, which celebrates its 30th anniversary in 2015, is on investigating development of basic mechanisms underlying Alzheimer's disease and related disorders, with particular attention to biomarkers and experimental new treatments. The Center is also continuing research on genetic risk factors associated with Alzheimer's disease, with its main priorities being to find causes, effective treatments, and prevention strategies, with its investigators also partnered with other Alzheimer's centers nationwide in evaluating promising new medications and other AD treatments. The Ellison Foundation, headquartered in Bellevue, Wash., was established in 2003 by Tom and Sue Ellison for
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *